Deal Announcements

ROXRO Pharma Closes $42.7 Million Financing Round

Wednesday, June 13, 2007 5:00:00 AM PDT | VentureDeal Staff

MENLO PARK, CA -- Pharmaceutical company ROXRO Pharma, Inc. said that it has closed a round of institutional financing, receiving $42.7 million.

ROXRO recently announced that it had completed Phase 3 clinical trials for ROX-888, its intranasal pain reliever.  If approved, the product would be the first non-opioid intranasal analgesic for treatment of acute pain.

Investors in the round were led by Prospect Venture Partners and Sutter Hill Ventures, and included Thomas Weisel Healthcare Venture Partners.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1